Building decline causes $172m bite for Brickworks
A construction slowdown in Australia and North America has forced a $172 million pre-tax write-down at brick manufacturer Brickworks.
A construction slowdown in Australia and North America has forced a $172 million pre-tax write-down at brick manufacturer Brickworks.
FDA accepts Mesoblast’s responses Biotech company Mesoblast has announced that the United States Food and Drug Administration (FDA) has accepted Mesoblast’s Biologics License Application (BLA) resubmission for Ryoncil (remestemcel-L) in the treatment of children with steroid-refractory acute graft versus host disease (SR-aGVHD). According to a statement, the FDA considers the resubmission to be a complete…
Veteran building products supplier Adbri could be the latest Australian manufacturer to fall to overseas control following an offer from a consortium of global building supplies group CRH plc and local premixed concrete supplier Barro Group. The partners have submitted a non-binding offer pitched at 9x EBITDA profit and a 41 percent premium to the…
Building products, property and investment group Brickworks’ latest annual report reveals a company still focused on manufacturing but transforming itself into a diverse powerhouse capable of sustainable, strong growth. The Sydney company reported a revenue rise but profit fall compared to the previous year, however this did not disguise the extraordinary improvement in the company’s…